EICHORPublic-registry site landscape for NCT03156361, “21 Day Comparison of Continuous Insulin Infusion Using HDV Insulin to Standard Insulin in Type 1 Diabetes Mellitus”, a Type1 Diabetes Mellitus study sponsored by Diasome Pharmaceuticals. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT03156361 (registry record) |
| Study title | 21 Day Comparison of Continuous Insulin Infusion Using HDV Insulin to Standard Insulin in Type 1 Diabetes Mellitus |
| Official title | A Randomized Controlled Trial Comparing 21 Days of Continuous Subcutaneous Insulin Infusion (CSII) Using Hepatic Directed Vesicle (HDV) Insulin to Standard CSII in Type 1 Diabetes Mellitus |
| Sponsor | Diasome Pharmaceuticals |
| Condition(s) | Type1 Diabetes Mellitus |
| Phase | PHASE2 |
| Listed sites | 1 |
| Site countries | United States |
Patient-friendly overview of this study: eichor.com/study/NCT03156361.
Eichor generates a preliminary site-risk snapshot for NCT03156361 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
← Eichor home · All tracked trials · Type1 Diabetes Mellitus studies · Weekly briefs
